| Description |
1 online resource |
| Contents |
Part 1: Review of Clinical Investigative Methods Chapter 1: Quantifying Insulin Action in Humans Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins Chapter 4: Measurement of Energy Expenditure Chapter 5: QUANTIFYING APPETITE AND SATIETY Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH Chapter 12: Omics: Potential role in early phase drug development Part 2: Preclinical Drug Development and Transitioning to Clinical Studies Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS -- CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview Chapter 18: Transitioning from Preclinical to Clinical Drug Development Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders Chapter 20: Early Phase Metabolic Research with Reference to Special Populations |
| Summary |
This book reviews techniques for assessing insulin action, insulin secretion and body composition, with reference to new drugs, in phase 1 & 2 studies. Adds to understanding of drug effects and non-drug treatment strategies in obesity and type 2 diabetes |
| Notes |
Includes index |
|
Online resource; title from PDF title page (EBSCO, viewed April 3, 2019) |
| Subject |
Drug development -- Research -- Methodology
|
|
Diabetes -- Research -- Methodology
|
|
Obesity -- Research -- Methodology
|
|
Fatty liver -- Research -- Methodology
|
|
Diabetes Mellitus -- drug therapy
|
|
Obesity -- drug therapy
|
|
Clinical Trials, Phase I as Topic -- methods
|
|
Clinical Trials, Phase II as Topic -- methods
|
|
Translational Research, Biomedical
|
|
MEDICAL -- Pharmacology.
|
| Form |
Electronic book
|
| Author |
Krentz, Andrew J., editor.
|
|
Weyer, Christian, editor
|
|
Hompesch, Marcus, editor.
|
| ISBN |
9783030117481 |
|
3030117480 |
|
